130 related articles for article (PubMed ID: 32822322)
1. [Factors affecting liver disease progression, with emphasis on the role of free radical reactions].
Hagymási K; Egresi A; Lengyel G; Blázovics A
Orv Hetil; 2020 Aug; 161(35):1441-1448. PubMed ID: 32822322
[TBL] [Abstract][Full Text] [Related]
2. [Control of hepatocellular carcinoma progression by the tumor microenvironment].
Clement B
Bull Acad Natl Med; 2012 Jan; 196(1):75-84. PubMed ID: 23259335
[TBL] [Abstract][Full Text] [Related]
3. [Incidence of hepatocellular carcinoma and consequent lessons for its management in Northeastern Hungary].
Papp R; Papp M; Tornai I; Vitális Z
Orv Hetil; 2016 Nov; 157(45):1793-1801. PubMed ID: 27817236
[TBL] [Abstract][Full Text] [Related]
4. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of hepatocellular carcinoma progression.
Ogunwobi OO; Harricharran T; Huaman J; Galuza A; Odumuwagun O; Tan Y; Ma GX; Nguyen MT
World J Gastroenterol; 2019 May; 25(19):2279-2293. PubMed ID: 31148900
[TBL] [Abstract][Full Text] [Related]
6. Role of free-radical reactions in liver diseases.
Fehér J; Vereckei A; Lengyel G
Acta Physiol Hung; 1992; 80(1-4):351-61. PubMed ID: 1345201
[TBL] [Abstract][Full Text] [Related]
7. [New aspects of the development of liver diseases – with special regard to the role of autophagy and microRNA].
Werling K
Orv Hetil; 2020 Aug; 161(35):1449-1455. PubMed ID: 32822323
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease.
Fontes A; Alemany-Pagès M; Oliveira PJ; Ramalho-Santos J; Zischka H; Azul AM
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426291
[TBL] [Abstract][Full Text] [Related]
9. [Antioxidant therapy in chronic liver diseases].
Lengyel G; Tulassay Z
Orv Hetil; 2006 Jun; 147(24):1113-8. PubMed ID: 16865855
[TBL] [Abstract][Full Text] [Related]
10. Obesity-associated mechanisms of hepatocarcinogenesis.
Karagozian R; Derdák Z; Baffy G
Metabolism; 2014 May; 63(5):607-17. PubMed ID: 24629562
[TBL] [Abstract][Full Text] [Related]
11. Iron and liver fibrosis: Mechanistic and clinical aspects.
Mehta KJ; Farnaud SJ; Sharp PA
World J Gastroenterol; 2019 Feb; 25(5):521-538. PubMed ID: 30774269
[TBL] [Abstract][Full Text] [Related]
12. [Rapid progression of hepatocellular carcinoma after surgery: apropos of a case and review of the literature].
Vergara Gómez M; Miquel Planas M; Gil Prades M; Dalmau Obrador B; Casas Rodrigo M; Sanchez Delgado J; Bella MR; Puig Domingo J
Gastroenterol Hepatol; 2010 Oct; 33(8):569-73. PubMed ID: 20627456
[TBL] [Abstract][Full Text] [Related]
13. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group.
Lancet; 1998 May; 351(9115):1535-9. PubMed ID: 10326535
[TBL] [Abstract][Full Text] [Related]
14. A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells.
Miyauchi Y; Yasuchika K; Fukumitsu K; Ishii T; Ogiso S; Minami T; Kojima H; Yamaoka R; Katayama H; Kawai T; Yoshitoshi-Uebayashi EY; Kita S; Yasuda K; Sasaki N; Uemoto S
Sci Rep; 2017 Aug; 7(1):9827. PubMed ID: 28851916
[TBL] [Abstract][Full Text] [Related]
15. Control of progression towards liver fibrosis and hepatocellular carcinoma by SOCS3 polymorphisms in chronic HCV-infected patients.
Jadid FZ; Chihab H; Alj HS; Elfihry R; Zaidane I; Tazi S; Badre W; Marchio A; El Filali KM; Tahiri M; Saile R; Pineau P; Ezzikouri S; Benjelloun S
Infect Genet Evol; 2018 Dec; 66():1-8. PubMed ID: 30172885
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress is bane in chronic liver diseases: Clinical and experimental perspective.
Ezhilarasan D
Arab J Gastroenterol; 2018 Jun; 19(2):56-64. PubMed ID: 29853428
[TBL] [Abstract][Full Text] [Related]
17. Implication of the Hedgehog pathway in hepatocellular carcinoma.
Della Corte CM; Viscardi G; Papaccio F; Esposito G; Martini G; Ciardiello D; Martinelli E; Ciardiello F; Morgillo F
World J Gastroenterol; 2017 Jun; 23(24):4330-4340. PubMed ID: 28706416
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
Keenan BP; Fong L; Kelley RK
J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
[TBL] [Abstract][Full Text] [Related]
19. Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases.
Ouda SM; Khairy AM; Sorour AE; Mikhail MN
Asian Pac J Cancer Prev; 2015; 16(17):7825-9. PubMed ID: 26625805
[TBL] [Abstract][Full Text] [Related]
20. Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis.
Crosas-Molist E; Bertran E; Fabregat I
Curr Pharm Des; 2015; 21(41):5964-76. PubMed ID: 26510436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
